Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

RNA Therapy Biotech Earns $44 Million in IPO

(bfishadow, WikimediaCommons)

1 October 2015. A biotechnology company developing therapies based on RNA, genetic material that sends signals to cells, raised $43.75 million in its initial public stock offering. Mirna Therapeutics Inc. in Austin, Texas issued 6.25 million shares today at $7.00, and trades on the Nasdaq exchange under the symbol MIRN. Its shares . . . → Read More: RNA Therapy Biotech Earns $44 Million in IPO

Synthetic Biology Company Raises $200 Million in IPO

(A. Kotok)

21 August 2015. Intrexon Corp., a company developing genomic solutions with synthetic biology, raised some $200 million in its initial public stock offering. The Germantown, Maryland enterprise issued 4,878,049 shares of common stock priced at $41.00, and traded on the New York Stock Exchange under the symbol XON. The company’s shares closed . . . → Read More: Synthetic Biology Company Raises $200 Million in IPO

Blood Disease Biotech Gains $120 Million in IPO

Red blood cells with sickle cell disease (NCATS.NIH.gov)

12 August 2015. Global Blood Therapeutics, a biotechnology company developing treatments for blood-related disorders, is raising $120 million in its initial public stock offering. The company, in South San Francisco, California and trading on the Nasdaq exchange under the symbol GBT, issued 6 million shares priced . . . → Read More: Blood Disease Biotech Gains $120 Million in IPO

Peanut Allergy Therapy Company Raises $160 Million in IPO

(National Institute of Food and Agriculture, USDA)

6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol AIMT. . . . → Read More: Peanut Allergy Therapy Company Raises $160 Million in IPO

Drug Delivery Biotech Raises $101.8 Million in IPO

(A. Kotok)

17 July 2015. Chiasma Inc., a biotechnology enterprise developing oral therapies to replace injected drugs, raised some $101.8 million in its initial public stock offering. The company — located in Newton, Massachusetts and Jerusalem, Israel — issued 6,365,000 shares at $16.00, and trades on the Nasdaq exchange under the symbol CHMA. Shares . . . → Read More: Drug Delivery Biotech Raises $101.8 Million in IPO

Rare Disease Therapy Company Raises $60 Million in IPO

(bfishadow, WikimediaCommons)

26 June 2015. Catabasis Pharmaceuticals Inc., a biotechnology company creating treatments for rare diseases and cholesterol-related disorders, is raising $60 million in its initial public stock offering, trading on the Nasdaq exchange under the symbol CATB. The Cambridge, Massachusetts enterprise yesterday priced its 5 million shares at $12.00, and as of 4:00 . . . → Read More: Rare Disease Therapy Company Raises $60 Million in IPO

Life Sciences Commercialization Firm to Crowdfund IPO

(bfishadow, WikimediaCommons)

4 June 2015. Innovation Economy Corporation is going public by skipping the usual route of hiring an investment bank, and instead will use crowdfunding to attract investors to its initial public offering of stock. The Riverside, California enterprise, that goes by the trade name ieCrowd, licenses life science and health-related technologies from . . . → Read More: Life Sciences Commercialization Firm to Crowdfund IPO

Cancer Biotech Raising $147 Million in IPO

(A. Kotok)

30 April 2015. Blueprint Medicines, a developer of cancer therapies that block enzymes supporting tumor growth, is raising some $146.7 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, listed on the NASDAQ exchange under the symbol BPMC, issued 8.15 million shares at $18.00.

The company began trading today with . . . → Read More: Cancer Biotech Raising $147 Million in IPO

Aduro Biotech Raises $108 million in IPO

Listeria bacteria (CDC.gov)

15 April 2015. Aduro Biotech Inc., a developer of immunotherapies to treat cancer, issued its initial public stock offering today that expects to net the company some $108 million, after issuing 7 million shares priced at $17.00. The Berkeley, California enterprise trades on the Nasdaq exchange under symbol ADRO. As of . . . → Read More: Aduro Biotech Raises $108 million in IPO

Immunotherapy Biotech Raising $45 Million in IPO

Herpes simplex viruses (Centers for Disease Control and Prevention)

12 March 2015. Genocea Biosciences Inc., a biotechnology company developing immunotherapies to treat genital herpes and other diseases, is raising $45 million in its initial public offering of stock. The Cambridge, Massachusetts enterprise is issuing 5,454,545 shares priced at $8.25. The company trades on the . . . → Read More: Immunotherapy Biotech Raising $45 Million in IPO